Reference

Comparative evaluation of contraceptive efficacy of norethisterone enanthate (200 mg) injectable contraceptive given every two or three months

Comparative evaluation of contraceptive efficacy of norethisterone enanthate (200 mg) injectable contraceptive given every two or three months. (Indian Council of Medical Research; Natl. Programme Res. Hum. Reprod., Div. Reprod. Biol. Fertil. Control, New Delhi, India). Contraception, 30(6), 561-74 (English) 1984. CODEN: CCPTAY. ISSN: 0010-7824. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) A total of 2388 subjects, 1181 for 60-day and 1207 for 90-day treatment regimens with norethisterone enanthate (NET EN) [3836-23-5] 200 mg injection, were obsd. for 24 mo, constituting 28,513 woman months. NET EN given at 60-day intervals provided adequate contraceptive protection. However, as compared to the published studies elsewhere, higher method failures were seen during the 1st 6 mo of NET EN usage, when all women were receiving the drug at 60-day intervals. The reasons for this discrepant observation in the present study cannot be explained. The higher method failures reported with 90-day regimen were mainly during the 3rd month following the injection, suggesting reduced contraceptive efficacy of the drug during this period. Thin built women (body wt. ￡40 kg) were at higher risk of involuntary pregnancy. Disrupted menstrual pattern was the major reason for discontinuation ranging 42-43 per 100 users at the end of 24 mo. Amenorrhea was the most common reason for discontinuation. No change in blood pressure was obsd. during contraceptive usage. The majority of NET EN users did not show any change in body wt. The overall continuation rates with NET EN were lower than those obsd. in similar conditions with Cu-T 200 mm2 intrauterine contraceptive device.

Pharmacokinetics of different doses of norethisterone enanthate

Pharmacokinetics of different doses of norethisterone enanthate. Fotherby, K.; Hamawi, A.; Howard, G.; Bye, P. G.; Elder, M. (R. Postgrad. Med. Sch., London, UK). Contraception, 29(4), 325-33 (English) 1984. CODEN: CCPTAY. ISSN: 0010-7824. DOCUMENT TYPE: Journal CA Section: 2 (Mammalian Hormones) Norethisterone enanthate (I) [3836-23-5] (50, 100, 150, and 300 mg) were administered i.m. to pre- and postmenopausal women and several men, and pharmacokinetic parameters were detd. for 8-10 wk. Due to wide inter-subject variations there were no differences in the pharmacokinetic parameters for the different groups, but there were correlations between the dose and the mean values for these parameters. The concn. of drug absorbed ranged 7.3-11.7 ng/mL and the half-life of elimination ranged 11.5-16.4 h for the 50-300 mg dose range. I was detectable in the serum for 67 days with the lowest dose and 105 days with the highest dose. The duration of the antifertility action of I cannot be increased by increasing the dose above the std. 200 mg; however, with an injection interval of 60 to 70 days, it seems likely that the dose could be reduced to 150 mg.